Inovio Pharmaceuticals, Inc.
Veridion Score
Composite trend over time
Why is INO moving today?
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for INO.
INO insider activity
Inovio Pharmaceuticals, Inc.
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for INO.
INO contract awards, year to date.
Public federal awards linked to this ticker.
INO lobbying filings, year to date.
Registered lobbying filings matched to Inovio Pharmaceuticals, Inc..